Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Saint-Herblain – page 6

611 clinical trials in Saint-Herblain, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint-Herblain at a glance
611
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

611 trials in Saint-Herblain

Open in trial search

Squamous cell carcinoma of head and neck

Recruiting

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Dyslipidaemia+1

Recruiting

Study of the efficacy and safety of inclisiran and a drug combination in patients with acute coronary syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer

Recruiting

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Squamous cell carcinoma of the hypopharynx+1

Recruiting

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Centre Leon Berard

Gastrointestinal cancer metastatic

Recruiting

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Recruiting

Study comparing firmonertinib with osimertinib or afatinib for patients with advanced lung cancer with uncommon EGFR mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Arrivent Biopharma Inc.

Neoplasm malignant

Recruiting

A Study of IPN60300 in Adults with Locally Advanced or Metastatic Solid Tumors to Assess Safety, Tolerability and Anti-Cancer Activity

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Ipsen Pharma

Adrenogenital syndrome

Recruiting

A Study Testing Atumelnant Compared to Placebo in Adults with Classic Congenital Adrenal Hyperplasia to Reduce Steroid Dose While Controlling Hormones

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Cardiac amyloidosis

Recruiting

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Coramitug
  • Sponsor:Novo Nordisk A/S

Neoplasm malignant+1

Recruiting

Study of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Novartis Pharma AG

Triple negative breast cancer

Recruiting

Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Saint-Herblain

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for breast cancer, lung cancer, and gastric cancer. Research includes novel therapeutic approaches targeting specific cancer types.

  • Triple-negative breast cancer interventions
  • Non-small cell lung cancer therapies
  • Gastrointestinal cancer treatments

Several trials are evaluating new antibody-drug conjugates and combination therapies for metastatic diseases.

02 Neurological Disorders

Studies targeting various neurological conditions, with emphasis on frontotemporal dementia and multiple sclerosis. Research focuses on innovative therapeutic approaches and disease-modifying treatments.

  • Dementia progression studies
  • Multiple sclerosis treatments
  • Sleep disorder interventions

Trials include evaluation of novel antibodies and assessment of long-term treatment efficacy.

03 Cardiovascular Studies

Comprehensive research into heart failure prevention, pulmonary hypertension, and cardiac rhythm disorders. Studies focus on innovative therapeutic approaches and preventive measures.

  • Heart failure prevention strategies
  • Pulmonary hypertension treatments
  • Cardiac rhythm management

Research includes long-term safety assessments and combination therapy evaluations.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.